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IN PRACTICE
Given the great genetic diversity of South Africa (SA)’s population 
and our high burden of disease, researchers and industry are keen to 
access the information contained in the DNA of our people. DNA 
from southern Africans is highly coveted, especially that derived 
from indigenous populations such as the San. Considered to be 
one of the oldest living populations on the planet, the San originate 
from the original hunter-gatherer populations that roamed the 
subcontinent before the arrival of populations from the north, either 
by land or by sea.
Preventing exploitation
With its history of colonisation and exploitation, Africa is now 
pushing back.[1] Many countries are tightening up the processes 
required for the export of DNA, and SA is no exception.[2] Our 
legislation clearly states that all DNA that leaves our shores requires 
an export permit in order to do so.[3] In the past, this was all that was 
required. This has allowed for the mass export of DNA, particularly 
by pharmaceutical companies conducting clinical trials, often for 
purposes of undertaking pharmacogenetic analyses.[4] However, as 
the problem of exploitation is still fresh in the minds of many South 
Africans, and with the realisation that this information could be used 
in the design of pharmaceuticals that might ultimately find their 
way back to the country and be used to treat its diverse peoples, 
the question arises whether this cycle could become a form of 
exploitation itself, if not correctly managed.
In response to these issues, which are now uppermost in the minds 
of many of the country’s regulators, the requirements for export of 
DNA are increasing. It is no longer sufficient just to complete an 
export permit request form supplied by the National Department of 
Health (NDoH); additional documentation that would apparently 
limit this exploitation is now required. This includes: (i) a material 
transfer agreement (MTA) that details what will be done with the 
DNA and how the information derived therefrom will be used; and 
(ii) where appropriate, approval from a research ethics committee 
when the DNA is being used for research purposes (Department of 
Health, personal communication 14 October 2016). Three important 
points that complement the above need to be considered: (i) the details 
in the MTA must reflect what is stipulated in the informed consent 
document, and the latter should ideally form part of the submission 
to the NDoH, although this is not a formal requirement at present; 
(ii) additional information regarding commercial exploitation of the 
data and possible benefit-sharing arrangements must be dealt with 
in the MTA; and (iii) information on the ownership/custodianship 
of the DNA (and its eventual destruction) and the data derived 
therefrom should be clearly set out.
There is a lack of agreement between the DoH, the research 
community, genetics service providers and industry regarding the 
need for an MTA. As a result, a discretionary approach has been 
requested based on whether or not the activity for which the DNA 
will be utilised is fee-for-service, research or has commercial intent.
Ownership of DNA and data is a thorny issue for which there is at 
present no consensual view.[2] It is not only important in the context 
of intellectual property ownership and commercialisation, but also 
with regard to judgemental and discriminatory attitudes that impact 
negatively on the individuals or populations concerned. The notion of 
genomic sovereignty, which refers to the need to regulate ownership 
of human genetic resources, is an area of intense debate.[5-7] So is the 
notion that commercialisation of DNA, which is derived from cells 
that constitute organs and tissues, could be viewed as ‘trading’, which 
in the context of organs is clearly not well viewed. And what about the 
data that are derived from DNA? How should these be viewed, since 
they not only contain information that may be of importance from 
the point of drug metabolism (in the case of pharmacogenetics), but 
can literally be used to ‘reconstruct’ an entire person and are likely to 
reveal that individual’s strengths and vulnerabilities? In the absence 
of oversight, nothing prevents the custodians of the DNA from 
utilising it for purposes other than those for which it was initially 
intended. Part of an oversight mechanism should be to ensure that 
the emerging and increasingly accepted norms governing informed 
consent should be adhered to.[8]
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Promoting innovation
Should we hinder the progress of science by restricting access to 
information that might, in the right hands, lead to the discovery of 
the next blockbuster drug? Should we not adopt a more liberal and 
open policy that would speed up the already rapid rate of discovery, 
ultimately to the benefit of all humankind?
Striking a balance
The answer probably lies somewhere in between. Individuals and 
populations that have been subjected to decades of repression and 
exploitation will tend to be protective of their assets (including 
DNA and the data derived therefrom), and this is understandable. 
Time, improvements in quality of life and the transfer of appropriate 
information will be required to alleviate some of the suffering 
generated by the ills of the past. Those who utilise DNA for research 
purposes and ultimately for commercial gain should be sensitive to 
the needs of the individuals and populations from whom the DNA 
originated. This means, for example, that the wholesale export of 
DNA by the pharmaceutical industry must be tempered by a set of 
checks and balances that include recognition of the source of the 
DNA and acknowledgement of the benefits that may be derived 
therefrom. If this argument is followed through to completion, 
mechanisms should be put into place to ensure that this recognition 
translates into tangible benefits to the affected communities. These 
benefits may take many forms that do not necessarily need to be 
monetary, but at the very least should influence pricing of the 
medications that emerge, which will be used on the very same 
populations that contributed to their design.
In summary, with the advent of next-generation sequencing, the 
power of computational biology (including bioinformatics) and 
the ability to manage large sets of data from which very precise 
information can be derived,[9] care should be taken to strike a 
balance between preventing exploitation and promoting innovation. 
Only by considering all the facts at hand and by anticipating possible 
future scenarios will we be able to ensure that human suffering is 
limited, whether it be though illness or through less tangible factors 
such as exploitation and discrimination. A brave and exciting new 
era is unfolding as technology opens up multiple new avenues that 
existed previously only in the realms of science fiction, and we 
should ensure that we are alert to the opportunities and do not miss 
or sink the boat.
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